Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Impact of Force Control of Hip Abductor Muscles in Healthy Adults and Individuals With Parkinson's Disease

4 mei 2026 bijgewerkt door: Chu-Ling Yen, Chang Gung Memorial Hospital

Impact of Force Control of Hip Abductor Muscles on Postural Control in Middle-aged and Older Adults and Individuals With Parkinson's Disease

Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. While previous studies have mainly focused on sagittal plane balance, the contribution of hip abductor muscles remains unclear, especially regarding their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. Previous studies have mainly focused on sagittal plane balance and have identified the important roles of ankle plantar flexors and knee extensors; however, the contribution of hip abductor muscles-key muscles for frontal plane stability-remains unclear, particularly in terms of their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD. Healthy young, middle-aged, and older adults will be recruited from the community, and individuals with PD will be recruited from the Department of Neurology. Healthy participants must be in good health, able to walk independently, demonstrate normal cognitive function, and provide informed consent, while those with neurological, cardiovascular, musculoskeletal, or other conditions affecting motor performance will be excluded. For individuals with PD, inclusion criteria will be a clinical diagnosis of idiopathic PD, Hoehn and Yahr stages 1 to 3, stable anti-PD medication use, and the ability to follow instructions and walk at least 10 m. Exclusion criteria will include psychiatric, immune, integumentary, or musculoskeletal disorders, neurological conditions other than PD, lower extremity pain, uncontrolled cardiovascular disease, or inability to provide informed consent. All participants will undergo a one-time assessment, including maximal voluntary isometric contraction, force steadiness, postural control, and gait performance.

Surface electromyography will be used to assess neuromuscular function, postural control will be evaluated using a force plate under multiple standing conditions, and gait parameters will be measured at both comfortable and fast walking speeds. Statistical analyses will be conducted using ANOVA to examine group differences.

Studietype

Observationeel

Inschrijving (Geschat)

210

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Taiwan
      • Taoyuan, Taiwan
        • Werving
        • Chang Gung Memorial Hospital
        • Contact:
      • Taoyuan, Taiwan
        • Werving
        • Chang Gung University
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

This study recruits healthy elderly individuals, healthy middle-aged individuals, healthy young individuals, and individuals with PD.

Beschrijving

Healthy people

Inclusion Criteria:

  • 20 to 39 years (young), 40 to 59 years (young), and 60-85 years (old)
  • generally in good health
  • able to walk 10 m independently
  • able to follow all instructions

Exclusion Criteria:

  • neurologic, psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
  • any pain over the lower extremities
  • uncontrolled cardiovascular diseases
  • unable to provide informed consent.

PD

Inclusion Criteria:

  • clinical diagnosis of idiopathic PD
  • Hoehn and Yahr stages 1 to 3
  • stable anti-PD medications
  • able to walk 10 m independently
  • able to follow all instructions

Exclusion Criteria:

  • psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
  • neurological conditions other than PD
  • any pain over the lower extremities
  • uncontrolled cardiovascular diseases
  • unable to provide informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Healthy people
General healthy adults
Ander: Age
We compare the young, middle-aged, and old groups
Ander: Parkinson's disease (PD)
We compare the healthy group and PD group.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Maximal force
Tijdsspanne: Baseline
The maximal force of lower extremity muscles
Baseline
Rate of torque development
Tijdsspanne: Baseline
The ability to rapidly generate muscle force
Baseline
Force steadiness
Tijdsspanne: Baseline
The ability to maintain a constant force output during a submaximal contraction
Baseline
Walking speed
Tijdsspanne: Baseline
The time taken by participants to walk a standardized distance
Baseline
Step Length
Tijdsspanne: Baseline
The linear distance between the two ankles, typically expressed in centimeter(cm).
Baseline
Cadence
Tijdsspanne: Baseline
The number of steps taken per minute (SPM)
Baseline
Single Support Time
Tijdsspanne: Baseline
The duration within the gait cycle when only one foot is in contact with the ground, typically measured in seconds or as a percentage of the total gait cycle.
Baseline
Double Support Time
Tijdsspanne: Baseline
The portion of the gait cycle where both feet are in contact with the ground, indicating the transition phase between steps, expressed as a percentage of the gait cycle or in seconds.
Baseline
Swing Time
Tijdsspanne: Baseline
The portion of the gait cycle where the foot is not in contact with the ground, moving forward to the next step. It is usually expressed as a percentage of the total gait cycle or in seconds.
Baseline
Timed Up-and-Go Test
Tijdsspanne: Baseline
Tthe time an individual takes to stand up from a chair, walk 3 meters, turn around, walk back, and sit down.
Baseline
Four Square Step Test
Tijdsspanne: Baseline
Participants will be required to perform four square step test by changing directions while stepping forward, sideway, and backward over a low obstacle as fast as possible.
Baseline
Center of Pressure (COP) Velocity in Balance Tasks
Tijdsspanne: Baseline
The speed at which the COP moves, calculated over the duration of the balance task. Higher velocities may reflect more dynamic balance adjustments or instability. Unit：millimeter per second(mm/s)
Baseline
Center of Pressure (COP) Area in Balance Tasks
Tijdsspanne: Baseline
The area covered by the COP trajectory during the balance task, providing an estimate of the sway envelope. A larger area might indicate poorer balance control. Unit：square millimeter(mm^2)
Baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Chang Gung Memorial Hospital

Medewerkers

Chang Gung University

Onderzoekers

  • Hoofdonderzoeker: Chu-Ling Yen, Chang Gung University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 augustus 2023

Primaire voltooiing (Geschat)

31 juli 2029

Studie voltooiing (Geschat)

31 juli 2029

Studieregistratiedata

Eerst ingediend

25 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

1 mei 2026

Eerst geplaatst (Werkelijk)

6 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

4 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 202202289A3

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren